Zobrazeno 1 - 10
of 567
pro vyhledávání: '"Joyce, O'Shaughnessy"'
Autor:
Sherko Kuemmel, Catherine Harper-Wynne, Yeon Hee Park, Fábio Franke, Michelino de Laurentiis, Eva Schumacher-Wulf, Daniel Eiger, Sarah Heeson, Andrés Cardona, Özgür Özyilkan, Flavia Morales-Vàsquez, Ciara Metcalfe, Marc Hafner, Eleonora Restuccia, Joyce O’Shaughnessy
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-14 (2024)
Abstract Background HER2-positive, estrogen receptor-positive breast cancer (HER2+, ER+ BC) is a distinct disease subtype associated with inferior response to chemotherapy plus HER2-targeted therapy compared with HER2+, ER-negative BC. Bi-directional
Externí odkaz:
https://doaj.org/article/e5f45a7c5b7e4bb7bb99b0bb30af3b2c
Autor:
Matthew P. Goetz, Irfan Cicin, Laura Testa, Sara M. Tolaney, Jens Huober, Valentina Guarneri, Stephen R. D. Johnston, Miguel Martin, Priya Rastogi, Nadia Harbeck, Ashwin Shahir, Ran Wei, Valérie André, Hope S. Rugo, Joyce O’Shaughnessy
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-7 (2024)
Abstract In monarchE, adjuvant abemaciclib significantly improved invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS), with sustained benefit beyond the 2-year treatment period. Abemaciclib dose reductions were allowed to p
Externí odkaz:
https://doaj.org/article/1378a75d34cd4a89ad1255e30c08bb59
Autor:
Kerigo Ndirangu, Rachel Goldgrub, Vanita Tongbram, Rajee Anton, Bagrat Lalayan, Joyce O’Shaughnessy, Sarah E Schellhorn
Publikováno v:
Journal of Comparative Effectiveness Research, Vol 13, Iss 6 (2024)
Aim: This systematic literature review aims to summarize the efficacy/effectiveness of treatments, including eribulin (ERI)-based and anti-human epidermal growth factor receptor 2 (HER2) treatments in advanced/metastatic HER2+ breast cancer. Method
Externí odkaz:
https://doaj.org/article/ec6775bd5d1b4893a90d684dd77a5e46
Autor:
Javier Cortes, Amin Haiderali, Min Huang, Wilbur Pan, Peter Schmid, Katherine G. Akers, Julie E. Park, Andrew M. Frederickson, Peter A. Fasching, Joyce O’Shaughnessy
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-13 (2023)
Abstract Background Patients with triple-negative breast cancer (TNBC) are generally younger and more likely to experience disease recurrence and have the shortest survival among all breast cancer patients. Recently, neoadjuvant delivery of the progr
Externí odkaz:
https://doaj.org/article/1a29cf73eae64c35bcb7538e9ebc0def
Autor:
R. C. Coombes, Sacha Howell, Simon R. Lord, Laura Kenny, Janine Mansi, Zahi Mitri, Carlo Palmieri, Linnea I. Chap, Paul Richards, William Gradishar, Sagar Sardesai, Jason Melear, Joyce O’Shaughnessy, Patrick Ward, Pavani Chalasani, Tobias Arkenau, Richard D. Baird, Rinath Jeselsohn, Simak Ali, Glen Clack, Ashwani Bahl, Stuart McIntosh, Matthew G. Krebs
Publikováno v:
Nature Communications, Vol 14, Iss 1, Pp 1-10 (2023)
Abstract Samuraciclib is a selective oral CDK7-inhibitor. A multi-modular, open-label Phase I study to evaluate safety and tolerability of samuraciclib in patients with advanced malignancies was designed (ClinicalTrials.gov: NCT03363893). Here we rep
Externí odkaz:
https://doaj.org/article/b14be29b81754bafad04d4aa37714251
Autor:
Jessica D. Lang, Tuong Vi V. Nguyen, Maren K. Levin, Page E. Blas, Heather L. Williams, Esther San Roman Rodriguez, Natalia Briones, Claudius Mueller, William Selleck, Sarah Moore, Victoria L. Zismann, William P.D. Hendricks, Virginia Espina, Joyce O’Shaughnessy
Publikováno v:
Biomarker Research, Vol 11, Iss 1, Pp 1-23 (2023)
Abstract Background A subset of triple-negative breast cancers (TNBCs) have homologous recombination deficiency with upregulation of compensatory DNA repair pathways. PIKTOR, a combination of TAK-228 (TORC1/2 inhibitor) and TAK-117 (PI3Kα inhibitor)
Externí odkaz:
https://doaj.org/article/52d8e016d5974151b746534d27914afc
Autor:
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Publikováno v:
npj Breast Cancer, Vol 10, Iss 1, Pp 1-1 (2024)
Externí odkaz:
https://doaj.org/article/abb00ee86ac244e6959147aeb2f4a725
Autor:
Komal Jhaveri, Joyce O’Shaughnessy, Peter A. Fasching, Sara M. Tolaney, Denise A. Yardley, Vikash Kumar Sharma, Chandroday Biswas, Astrid Thuerigen, Purnima Pathak, Hope S. Rugo
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 15 (2023)
Background: Current standard-of-care first-line treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2−) advanced breast cancer (ABC) is cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) + end
Externí odkaz:
https://doaj.org/article/f9fa04a73b63440b97588ebecf3c53a7
Autor:
Neelima Vidula, Andrew Lipman, Shumei Kato, Caroline Weipert, Katherine Hesler, Georges Azzi, Ahmed Elkhanany, Dejan Juric, Estelamari Rodriguez, Colleen Faulkner, Paul Makhlouf, Kristin Price, Joyce O’Shaughnessy, Aditya Bardia
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-7 (2022)
Abstract We evaluate microsatellite instability-high (MSI-H) status with cell-free DNA (cfDNA) in metastatic breast cancer (MBC) and the association with clinico-genomic characteristics. Patients with MSI-H in cfDNA (Guardant360®, 74 gene next-gener
Externí odkaz:
https://doaj.org/article/f65bfda34691462a94c380daea7a2c6a
Autor:
Hope S. Rugo, Sara M. Tolaney, Delphine Loirat, Kevin Punie, Aditya Bardia, Sara A. Hurvitz, Joyce O’Shaughnessy, Javier Cortés, Véronique Diéras, Lisa A. Carey, Luca Gianni, Martine J. Piccart, Sibylle Loibl, David M. Goldenberg, Quan Hong, Martin Olivo, Loretta M. Itri, Kevin Kalinsky
Publikováno v:
npj Breast Cancer, Vol 8, Iss 1, Pp 1-10 (2022)
Abstract Sacituzumab govitecan (SG) is an anti-Trop-2 antibody-drug conjugate with an SN-38 payload. In the ASCENT study, patients with metastatic triple-negative breast cancer (mTNBC) relapsed/refractory to ≥2 prior chemotherapy regimens (≥1 in
Externí odkaz:
https://doaj.org/article/d9b62774a9d24a4da2cdc08d0bf5a33c